MSLN and pancreatic adenocarcinoma: Mesothelin expression has been identified in many solid tumors, most robustly in mesothelioma, epithelial ovarian cancer, and pancreatic adenocarcinoma, but also in lung and uterine malignancies as well as cholangiocarcinoma [32,33,34,35,36].